[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

2015 Strategies in the US Hospital Tumor Marker Testing Market

February 2015 | 567 pages | ID: 2069ECB5BA3EN
Venture Planning Group

US$ 5,200.00 US$ 6,500.00 -20 %

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This new report from VPGMarketResearch contains 567 pages, 50 tables, and presents a comprehensive analysis of the US hospital tumor market testing market, including:
  • Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.
  • Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.
  • Test volume and sales forecasts for 40 tumor markers performed in US hospitals.
  • Current instrumentation technologies and feature comparison of leading analyzers.
  • Sales and market shares of leading suppliers.
  • Emerging diagnostic technologies and their potential market applications.
  • Product development opportunities.
  • Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.
  • Business opportunities and strategic recommendations for suppliers.
Contains 567 pages and 50 tables
Introduction

Worldwide Market and Technology Overview

A. Cancer Statistics and Etiology
1. BREST CANCER
2. LUNG CANCER
3. COLON AND RECTUM CANCER
4. PROSTATE CANCER
5. STOMACH CANCER
6. LEUKEMIA
7. LYMPHOMA
8. ORAL CANCER
9. SKIN CANCER
10. UTERINE CANCER
11. OVARIAN CANCER
12. BLADDER CANCER
B. Major Current And Emerging Cancer Diagnostic Tests
  1. INTRODUCTION
2. TUMOR MARKER CLASSIFICATION
3. ACTH
4. ALPHA-FETOPROTEIN (AFP)
5. BETA-2 MICROGLOBULIN
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. CALCITONIN
10. CARCINOEMBRIONIC ANTIGEN (CEA)
11. ESTROGEN AND PROGESTERONE RECEPTORS
12. FERRITIN
13. GASTRIN
14. HUMAN CHORIONIC GONADOTROPIN (HCG)
15. INSULIN
16. NSE
17. OCCULT BLOOD
18. PAP SMEAR/HPV
19. PROSTATIC ACID PHOSPHATASE (PAP)
20. PROSTATE-SPECIFIC ANTIGEN (PSA)
21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)
22. T AND B LYMPHOCYTES
23. TDT
24. THYROGLOBULIN
25. TISSUE POLYPEPTIDE ANTIGEN (TPA)
26. BIOCHEMICAL TUMOR MARKERS
ADA
B-Protein
PNP
5'-Nucleotidase
27. ONCOGENES
Abl/abl-bcr
AIB1
BCL-2
BRCA1
CD44
C-fos
C-myb
C-myc
CYP-17
Erb-B
HPC1
N-myc
P40
P51
P53
PIK3CA
PTI-1
Ras
Reg
Sis
Src
28. POLYPEPTIDE GROWTH FACTORS
Basic Fibroblast Growth Factor
Beta-TGF
Cachectin (TNT)
Calmodulin
ECFR
Nerve Growth Factor (NGF)
Epidermal Growth Factor (EGF)
Ornithine Decarboxylase
Transferrin
Transforming Growth Factor-Alpha
29. ECTOPIC HORMONES
30. COLONY STIMULATING FACTORS
31. LYMPHOKINES
Alpha-Interferon
B Cell Growth Factors
B Cell Growth Factor (BCGF)
Gamma-Interferon
Interleukin-1 (IL-1)
Macrophage Activating Factor
32. IMMUNOHISTOCHEMICAL STAINS
33. EMERGING TUMOR MARKERS
N-Acetylglucosamine
Actin
Alpha-Actin
Antineuronal Antibodies
7B2
B72.3
Bax
BCD-F9
BLCA-4
Blood Group Antigens A,B,H
CA
CA 72-4/TAG-72
CA
CA-242
CA-549
CAM
CAR-3
Cathepsin-D
Chromogranin A and B
Cluster 1 Antigen
Cluster-5/5A Antigen
CTA
CU18
DR-70
DU-PAN-2
Endometrial Bleeding Associated Factor
Endostatin
Epithelial Membrane Antigen
Feulgen Hydrolysis
Fibronectin
FSH
(1->3)-L-fucosyltransferase
Gastrin-Releasing Peptide (GRP)
GDCFP-15
Glucagon
Glycoamines
H23
Her-2
Human Carcinoma Antigen
HPA
HSP27
Intermediate Filaments
Cytokeratins/CK18/Cyfra 21-1
Desmin
Gliofibrillary Acid Protein
Neurofilaments
Vimentin
KA
Kinases
KP16D3
LAI
Leukocyte Common Antigen
Lewis Antigens
Lysophosphatidic Acid (LPA)
Ma 695/Ma
MABDF3
MAG
ME1
Minactivin
MN/CA9
MSA
Mucin Cancer Antigen (MCA)
Multiple Tumor Suppressor
Myosin
NEA-130
NMP22
OA-519
Opiod Peptides
P-glycoprotein
Pancreatic Oncofetal Antigen (POA)
Placental Lactogen
PR92
Proliferative Index, Ki-67
Px
RB Inactivation/Deletion
Ret
SCCL
Selectin
Sialic Acid
Sialyl SSEA-1/SLX
SN10
Somatostatin
TA-90
TABA
Tachykinin
TAG
TPS
Troponin
Tubulin
VCAM
VEGF
Villen
C. Instrumentation Review And Market Needs
1. ABBOTT AXSYM
2. ABBOTT ARCHITECT C4000
3. ABBOTT ARCHITECT I200   SERIES
4. ABBOTT ARCHITECT CI820   SYSTEM
5. BECKMAN COULTER UNICEL SERIES
6. BECKMAN COULTER ACCESS
7. BINDING SITE ESP600
8. BIOMERIEUX MINI VIDAS
9. CAROLINA CHEMISTRIES BIOLIS 24I
10. DIASORIN LIAISON
11. HORIBA ABX PENTRA
12. INVERNESS DS2
13. J&J VITROS ECI/ECIQ
14. J&J VITROS 3600
15. J&J VITROS 5600
16. OLYMPUS AU5400
17. OLYMPUS AU3000I
18. OLYMPUS AU2700
19. ROCHE MODULAR ANALYTICS
20. ROCHE COBAS INTEGRA
21. ROCHE COBAS INTEGRA 40   PLUS
22. ROCHE ELECSYS
23. ROCHE COBAS C311
24. SIEMENS ADVIA CENTAUR
25. SIEMENS DIMENSION
26. SIEMENS DIMENSION RXL MAX
27. SIEMENS DIMENSION VISTA
28. SIEMENS IMMULITE
29. SIEMENS STRATUS
30. TOSOH AIA-SERIES
31. VITAL DIAGNOSTICS ATAC 8000
32. VITAL DIAGNOSTICS ENVOY
D. Current and Emerging Technologies
1. MONOCLONAL AND POLYCLONAL ANTIBODIES
2. IMMUNOASSAYS
  a. Technological Principle
  b. Radioimmunoassay (RIA)
  c. Enzyme Immunoassays (EIA)
Overview
ELISA
Immunofiltration
Particle-Membrane Capture Immunoassay
Enzyme Amplification
  d. Fluorescent Immunoassays
  e. Luminescence
Chemiluminescence
Bioluminescence
  f. Latex Agglutination
  g. Immunoprecipitation
H. Affinity Chromatographu
  e. Liposome Flow-Injection Immunoassay
3. MOLECULAR DIAGNOSTICS
  a. Technology Overview
  b. Amplification Methods
PCR
DAP-PCR
Immuno-PCR
QC-PCR
CAR
DNA
HPA
LCR
NASBA
QBR
SDA
3 SR, and others
4. CHROMOSOME ANALYSIS
  a. Chronic Myelogenous Leukemia (CML)
  b. Acute Myeloid Leukemia (AML)
  c. Acute Lymphoblastic Leukemia (ALL)
  d. Malignant Lymphomas Lymphoid Malignancies
  e. Chronic Lymphocytic Leukemia (CLL)
  f. Solid Cancers
  g. Chromosomal Translocation and Oncogenes
5. ARTIFICIAL INTELLIGENCE
6. FLOW CYTOMETRY
7. TWO DIMENSIONAL GEL ELECTROPHORESIS (2-DGE)
8. BIOSENSORS
9. COMPETING/COMPLEMENTING TECHNOLOGIES
  a. CT
  b. MRI
  c. NMR
  d. PET
  e. Photonics Spectroscopy
E. Personal Testing

U.S.A.

A. Executive Summary
B. Business Environment
1. HEALTH CARE EXPENDITURES
2. COST CONSCIOUSNESS
3. INDUSTRY CONSOLIDATION
4. MANAGED CARE
5. HOSPITALS
6. ADMISSIONS
7. LENGTH OF STAY
8. INDUSTRY DIVERSIFICATION
9. PHYSICIAN DEMOGRAPHICS
10. POPULATION AGING
  a. Chronic Illness
  b. Disease Incidence
  c. Susceptibility to Iatrogenesis
  d. Multiple Illness Cases
11. LABORATORY REGULATIONS
C. Market Structure
1. CENTRALIZED TESTING
  a. Hospitals
  b. Commercial/Private Laboratories
2. POT/DECENTRALIZED TESTING
  a. Physician Offices/Group Practices
  b. Cancer Clinics
  c. Point-Of-Care Testing
  d. Other Decentralized Testing Locations
D. Market Size, Growth and Major Suppliers Sales, Instrument Placements and Market Shares

MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products

DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
1. MARKETING APPROACHES
2. PRODUCT COMPLEXITY
3. CUSTOMER PREFERENCE
4. ESTABLISHED SUPPLIERS
5. EMERGING SUPPLIERS
6. MAJOR TYPES OF DISTRIBUTORS
7. MARKET SEGMENTATION FACTOR
POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
COMPETITIVE PROFILES
Abbott
AdnaGen
Applied Gene Technologies
Arca
Beckman Coulter/Danaher
Becton Dickinson
Biomedical Diagnostics
bioMerieux
Bio-Rad
Cepheid
Correlogic Systems
Dako
Decode
Diadexus
Diagnocure
Diasorin
Eiken Chemical
Enterix
Enzo Biochem
Epigenomics
Exact Sciences
Fujirebio
Gen-Probe
Guided Therapeutics
Hologic
Ipsogen
Kreatech
Kyowa Medex
Life Technologies
Mackay Life Sciences
Myriad Genetics
Nanogen Elitech
OncoLab
Otho-Clinical Diagnostics
Panacea Pharmaceuticals
Polartechnics
Polymedco
PreMD
Qiagen
Radient Pharmaceuticals
Roche
Scienion
Sequenom
Siemens Healthcare
Takara Bio
Targeted Diagnostics & Therapeutics
Tosoh
Veridex
Wako Pure Chemicals
Wallac/PE
Zila

LIST OF TABLES

Tumor Marker Classification
Major Companies Developing or Marketing ACTH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing Beta-2 Microglobulin Tests
Major Companies Developing or Marketing CA 15-3/27.29 Tests
Major Companies Developing or Marketing CA 19-9 Tests
Major Companies Developing or Marketing CA 125 Tests
Major Companies Developing or Marketing Calcitonin Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Estrogen Receptor Tests
Major Companies Developing or Marketing Progesterone Receptor Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Gastrin Tests
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing Insulin Tests
Major Companies Developing or Marketing NSE Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing PAP Smear/HPV Tests
Major Companies Developing or Marketing PAP Tests
Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications In Cancer Diagnosis
Oncogenes Potential Applications In Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests Growth Factors Potential ApplicationsIn Cancer Diagnosis
Colony Stimulating Factors Potential Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis
Immunohistochemical Stains Potential Applications in Cancer Diagnosis
Executive Summary Table: U.S., Hospital Cancer Diagnostic Test Volume and Sales Forecast
U.S., Estimated New Cancer Cases and Deaths
U.S., Estimated Cancer Death Rates Per 100,00 Population
U.S., Laboratories Performing Cancer Diagnostic Tests
U.S., Hospital Laboratories Performing Cancer Diagnostics Tests by Bed Size
U.S., Hospital Laboratories Major Cancer Diagnostic Test Volume Forecast by Test
U.S., Total Cancer Diagnostics Sales By Major Supplier
U.S., ACTH Testing Market Diagnostics Sales by Major Supplier
U.S., AFP Testing Market Diagnostics Sales by Major Supplier
U.S., Beta-2 Migroblolulin Testing Market Diagnostics Sales by Major Supplier
U.S., CA 15-3/27.29 Testing Market Diagnostics Sales by Major Supplier
U.S., CA 19-9 Testing Market Diagnostics Sales by Major Supplier
U.S., CA 125 Testing Market Diagnostics Sales by Major Supplier
U.S., CEA Testing Market Diagnostics Sales by Major Supplier
U.S., Ferritin Testing Market Diagnostics Sales by Major Supplier
U.S., HCG Testing Market Diagnostics Sales by Major Supplier
U.S., Insulin Testing Market Diagnostics Sales by Major Supplier
U.S., Parathyroid Hormone Testing Market Diagnostics Sales by Major Supplier
U.S., PAP Testing Market Diagnostics Sales by Major Supplier
U.S., Progesterone Receptor Testing Market Diagnostics Sales by Major Supplier
U.S., PSA Testing Market Diagnostics Sales by Major Supplier


More Publications